Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density
Authors:
- Gal Dubnov-RazGDGal Dubnov-Raz
- Harri HemiläHarri Hemilä
- Yael VurembrandYVYael Vurembrand
- Jacob KuintJKJacob Kuint
- Ayala Maayan-MetzgerAMAyala Maayan-Metzger
- 1 March 2012
- journal article
- Published by Elsevier in Early Human Development
- Vol. 88 (3) , 191-194
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Risk of Low Bone Mineral Density Associated With Psychotropic Medications and Mental Disorders in Postmenopausal WomenJournal of Clinical Psychopharmacology, 2011
- Update in Serotonin and BoneThe Journal of Clinical Endocrinology & Metabolism, 2010
- A Cross-Sectional Evaluation of the Effect of Risperidone and Selective Serotonin Reuptake Inhibitors on Bone Mineral Density in BoysThe Journal of Clinical Psychiatry, 2010
- Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A reviewClinical Therapeutics, 2009
- Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in NewbornsPediatrics, 2008
- Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm NeonatesPediatrics, 2007
- Long‐term fluoxetine administration does not result in major changes in bone architecture and strength in growing ratsJournal of Cellular Biochemistry, 2006
- Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2006
- Perinatal DepressionObstetrics & Gynecology, 2005
- Umbilical Venous IGF-1 Concentration, Neonatal Bone Mass, and Body CompositionJournal of Bone and Mineral Research, 2004